Microscopic Polyangiitis

Also known as: Microscopic polyarteritis

DrugDrug NameDrug Description
DB00073RituximabRituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences [A40017], [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
DrugDrug NameTargetType
DB00073RituximabB-lymphocyte antigen CD20target
DrugDrug NamePhaseStatusCount
DB00688Mycophenolate mofetil1Completed1
DB00993Azathioprine2Completed1
DB12330Blisibimod2Withdrawn1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Unknown Status1
DB00065Infliximab2Completed1
DB00563Methotrexate2Unknown Status1
DB00959Methylprednisolone2Completed1
DB00688Mycophenolate mofetil2Completed1
DB00704Naltrexone2Recruiting1
DB00860Prednisolone2Completed1
DB00993Azathioprine2 / 3Completed1
DB00531Cyclophosphamide2 / 3Completed2
DB00959Methylprednisolone2 / 3Completed1
DB00635Prednisone2 / 3Completed1
DB00073Rituximab2 / 3Completed1
DB00993Azathioprine3Active Not Recruiting1
DB00993Azathioprine3Completed1
DB00073Rituximab3Active Not Recruiting1
DB00073Rituximab3Completed2
DB00087Alemtuzumab4Unknown Status1
DB00993Azathioprine4Unknown Status1
DB00531Cyclophosphamide4Unknown Status1
DB00860Prednisolone4Recruiting1
DB00635Prednisone4Completed1
DB00073Rituximab4Completed1
DB00073Rituximab4Recruiting1
DB00065InfliximabNot AvailableCompleted1
DB00073RituximabNot AvailableCompleted2